Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2G4HB
|
|||
| Drug Name |
Bulevirtide
|
|||
| Synonyms |
Lipopeptide
Click to Show/Hide
|
|||
| Drug Type |
Peptide
|
|||
| Indication | Hepatitis D virus infection [ICD-11: 1E51.2; ICD-10: B16-B18] | Approved | [1] | |
| Company |
MYR Pharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sodium/bile acid cotransporter (SLC10A1) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Bile secretion | |||
| Hepatitis B | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03852719) Phase 3 Study of Bulevirtide in Patients With CHD. U.S. National Institutes of Health. | |||
| REF 2 | Bulevirtide: First Approval. Drugs. 2020 Oct;80(15):1601-1605. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.